Targeting cancer by binding iron: Dissecting cellular signaling pathways

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Advanced cancers with resistance and metastasis require novel therapies.
• Cancer cells exhibit altered iron metabolism, crucial for proliferation.
• Existing iron chelators show anti-neoplastic effects, validating iron metabolism as a therapeutic target.

Purpose of the Study:

• To review recent research on targeting cancer cell iron metabolism.
• To focus on novel and potent di-2-pyridylketone thiosemicarbazone (DpT) ligands.
• To elucidate the molecular mechanisms of DpT ligands in cancer treatment.

Main Methods:

• Review of recent studies on iron chelation in cancer.
• Analysis of DpT ligands' effects on cellular iron metabolism.
• Investigation of DpT ligands' impact on cancer-related signaling pathways.

Main Results:

• Iron chelation, particularly with DpT ligands, demonstrates potent anti-cancer activity.
• DpT ligands inhibit proliferation, epithelial-mesenchymal transition (EMT), and metastasis.
• These ligands modulate critical signaling pathways including AKT, ERK, JNK, p38, STAT3, TGF-β, Wnt, and autophagy.

Conclusions:

• Novel DpT ligands represent a promising therapeutic strategy for advanced cancers.
• Targeting iron metabolism offers a viable approach to overcome cancer resistance and metastasis.
• These findings support the clinical potential of DpT ligands in cancer therapy.